Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis

International Journal of Cancer

Volumn 103, Issue 4, 2003, Pages 445-454

  Güner, Dilek ^a   Sturm, Isrid ^a   Hemmati, Philipp ^a   Hermann, Sandra ^a   Hauptmann, Steffen ^a   Wurm, Reinhard ^a   Budach, Volker ^a   Dörken, Bernd ^a   Lorenz, Matthias ^b   Daniel, Peter T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Bax; Cyclin D1; Esophageal squamous cell carcinoma; p16INK4a; p21 CIP WAF 1; p53; Rb

Indexed keywords

CYCLIN D1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; EXON; FEMALE; GENE DISRUPTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RB GENE; RETROSPECTIVE STUDY; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; FEMALE; G1 PHASE; GENES, P53; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGRESSION ANALYSIS; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0037428655     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10850     Document Type: Article

References (51)

1. Roth J, Putnam JB, Rich TA, Forastiere AA. Cancer of the esophagus. In: DeVita VT, Rosenberg SA, Hellmann S, eds. Cancer. Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997. 980-1021.
2. ink4a/CDKN2 identifies patients with good prognosis. J Clin Oncol 2001;19:2272-81.
3. Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT. Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-74.
4. Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B, Daniel PT. Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer 2001;99:589-96.
5. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-8.
6. Gascoyne RD, Krajewska M, Krajewsky S, Connors JM, Reed JC. Prognostic significance of BAX protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:3173-8.
7. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998;16:2583-90.
8. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Büchler MW. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998;43:414-21.
9. ARF induces p53 and Bax-independent apoptosis. Oncogene 2002;21:3149-61.
10. von Haefen C, Wieder T, Gillissen B, Stärck L, Graupner V, Dörken B, Daniel PT. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene, 2002;21:4009-19.
11. Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B, Daniel PT. The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1 overexpressing breast cancer cell lines. Oncogene 2002;21:227-38.
12. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dörken B, Brown R. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood 1999;94:1100-7.
13. Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dörken B, Daniel PT. BAX expression in benign and malignant thyroid tumors: Dysregulation of wild type p53 is associated with a high BAX and p21 expression in thyroid carcinoma. Int J Cancer 2001;92:805-11.
14. Sturm I, Papadopoulos S, Hillebrand T, Benter T, Lück H-J, Wolff G, Dörken B, Daniel PT. Impaired BAX protein expression in breast cancer: Mutational analysis of the BAX and the p53 gene. Int J Cancer 2000;87:517-21.
15. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, Kitajima M. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997;3:2229-36.
16. Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B, Daniel PT. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia 2001;16:1035-44.
17. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dörken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995;60:854-9.
18. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD, Dörken B. Overexpression of the death-promoting gene bax-α which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 1996;97:2651-9.
19. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
20. Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, McDaniel TK, Newkirk C, Resau JH, Sridhara R. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 1992;52:6525-30.
21. Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S, McDaniel T, Boynton RF, Zou ZQ. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 1993;53:1889-94.
22. Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Ishida K, Saito K, Satodate R. Aberrations of tumor-suppressor genes (p53, apc, mcc and Rb) in esophageal squamous-cell carcinoma. Int J Cancer 1994;57:21-5.
23. Morgan RJ, Newcomb PV, Bailey M, Hardwick RH, Alderson D. Loss of heterozygosity at microsatellite marker sites for tumour suppressor genes in oesophageal adenocarcinoma. Eur J Surg Oncol 1998;24:34-7.
24. Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Inoue M, Yano M, Kimura Y, Yamamoto M, Monden M. Effect of cyclin D1 and associated proteins on proliferation of esophageal squamous cell carcinoma. Int J Oncol 1998;13:455-60.
25. zur Hausen A, Sarbia M, Heep H, Willers R, Gabbert HE. Retinoblastoma-protein (pRb) expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer 1999;84:618-22.
26. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review. Int J Cancer 1996;69:225-35.
27. Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, Kano M. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999;80:1281-8.
28. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
29. 1 arrest checkpoint in response to DNA damage. Mol Cell Biol 1998;18:378-87.
30. Daniel PT. Dissecting the pathways to death. Leukemia 2000;14:2035-44.
31. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001;20:2225-34.
32. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61.
33. Hollstein MC, Peri L, Mandard AM, Welsh JA, Montesano R, Metcalf RA, Bak M, Harris CC. Genetic analysis of human esophageal tumors from two high incidence geographic areas: Frequent p53 base substitutions and absence of ras mutations. Cancer Res 1991;51:4102-6.
34. Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer 1999;86:1396-405.
35. Patel DD, Bhatavdekar JM, Chikhlikar PR, Patel YV, Shah NG, Ghosh N, Suthar TP, Balar DB. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: An immunohistochemical approach. J Surg Oncol 1997;65:111-6.
36. Pomp J, Davelaar J, Blom J, van Krimpen C, Zwinderman A, Quint W, Immerzeel J. Radiotherapy for oesophagus carcinoma: The impact of p53 on treatment outcome. Radiother Oncol 1998;46:179-84.
37. Ribeiro UJ, Finkelstein SD, Safatle RA, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998;83:7-18.
38. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, Mori T. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Arch A Pathol Anat Histopathol 1993;422:271-6.
39. waf1/cip1) influence the sensitivity of chemoradiation therapy for esophageal cancer. Hepatogastroenterology 1998;45:1497-504.
40. Uchino S, Saito T, Inomata M, Osawa N, Chikuba K, Etoh K, Kobayashi M. Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol 1996;26:287-92.
41. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J, Alderson D. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 1997;23:30-5.
42. Lam KY, Tsao SW, Zhang D, Law S, He D, Ma L, Wong J. Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: A prospective clinico-pathologic study and survival analysis of 70 patients. Int J Cancer 1997;74:212-9.
43. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
44. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996;16:4961-71.
45. Daniel PT, Gillissen B, Sturm I. Tumour genotype and response to cytotoxic gene therapy. In: Subramanian G, ed. Manufacturing of Gene Therapeutics. New York: Kluwer Academic/Plenum, 2001, 59-98.
46. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997;94:2345-9.
47. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, Dörken B. Induction of the death-promoting gene bax-α sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 1996;67:138-41.
48. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
49. Jürgensmeier JM, Xie ZH, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998;95:4997-5002.
50. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B, Daniel PT. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2-ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000;14:1606-13.
51. Torzewski M, Sarbia M, Heep H, Dutkowski P, Willers R, Gabbert HE. Expression of Bcl-X(L), an antiapoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma. Clin Cancer Res 1998;4:577-83.